Coexistent Tuberculosis of Spine and Chronic Myeloid Leukemia: Resolving the Diagnostic Dilemma and Management
Arvind Jayaswal, Sanjay Yadav, Ankur Goswami, G Vijayraghavan
Citation Information :
Jayaswal A, Yadav S, Goswami A, Vijayraghavan G. Coexistent Tuberculosis of Spine and Chronic Myeloid Leukemia: Resolving the Diagnostic Dilemma and Management. J Postgrad Med Edu Res 2015; 49 (2):85-87.
Yadav S, Jayaswal A, Vijayraghavan G, Goswami A. Coexistent Tuberculosis of Spine and Chronic Myeloid Leukemia: Resolving the Diagnostic Dilemma and Management. J Postgrad Med Edu Res 2015;49(2):85-87.
Tuberculosis and malignancy. Q J Med 2010;103(7):461-487.
Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances. Haematologica 2005;90(8): 1110-1115.
Spinal cord compression of dual etiology, multiple myeloma and spinal tuberculosis. Leuk Lymphoma 2002;43(2):427-428.
Causes of misdiagnosis and mistreatment of spinal TB with radiotherapy in non-endemic areas: a pitfall in diagnosis and treatment. Spine 2005;30(11):E300-304.
Differentiation between spinal tumors and infections with magnetic resonance imaging. Spine 1991;16(Suppl 8):334-338.
Problems in distinguishing spinal tuberculosis from neoplasia on MRI. Neuroradiology 1996;38(suppl 1):97-104.
Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56(2):69-83.
Survival of virulent mycobacterium tuberculosis involves preventing apoptosis induced by Bcl-2 upregulation and release resulting from necrosis in J774 macrophages. Microbiol Immunol 2005;49(9): 845-852.
Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog 2007;3(7):e110
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105(6):2473-2479.
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004;103(5):538-544.